Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Regier Voth

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
JCO Precision Oncology|July 16, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid TumorsGeraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue SarcomasGeraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, et al.
Cancer Research|October 26, 2018
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line PanelAnne Monks, Yingdong Zhao, Curtis Hose, et al.
Oncotarget|November 20, 2020
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomasGeraldine O'Sullivan Coyne, Shivaani Kummar, Robert S Meehan, et al.
Cancer Research|November 17, 2019
Clinical Evolution of Epithelial-Mesenchymal Transition in Human CarcinomasTony Navas, Robert J Kinders, Scott M Lawrence, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
JCO Precision Oncology|July 16, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid TumorsGeraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue SarcomasGeraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, et al.
Cancer Research|October 26, 2018
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line PanelAnne Monks, Yingdong Zhao, Curtis Hose, et al.
Oncotarget|November 20, 2020
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomasGeraldine O'Sullivan Coyne, Shivaani Kummar, Robert S Meehan, et al.
Cancer Research|November 17, 2019
Clinical Evolution of Epithelial-Mesenchymal Transition in Human CarcinomasTony Navas, Robert J Kinders, Scott M Lawrence, et al.
Pageof 2